- Home
- CMPO vs GERN Comparison
CMPO vs GERN Comparison
Compare CMPO & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPO
- GERN
- Stock Information
- Founded
- CMPO 2000
- GERN 1990
- Country
- CMPO United States
- GERN United States
- Employees
- CMPO N/A
- GERN N/A
- Industry
- CMPO Finance: Consumer Services
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- CMPO Finance
- GERN Health Care
- Exchange
- CMPO Nasdaq
- GERN Nasdaq
- Market Cap
- CMPO 1.5B
- GERN 1.5B
- IPO Year
- CMPO N/A
- GERN 1996
- Fundamental
- Price
- CMPO $16.11
- GERN $2.57
- Analyst Decision
- CMPO Strong Buy
- GERN Strong Buy
- Analyst Count
- CMPO 8
- GERN 11
- Target Price
- CMPO $16.81
- GERN $6.82
- AVG Volume (30 Days)
- CMPO 1.0M
- GERN 12.4M
- Earning Date
- CMPO 03-05-2025
- GERN 02-26-2025
- Dividend Yield
- CMPO 1.86%
- GERN N/A
- EPS Growth
- CMPO N/A
- GERN N/A
- EPS
- CMPO N/A
- GERN N/A
- Revenue
- CMPO $419,612,000.00
- GERN $29,480,000.00
- Revenue This Year
- CMPO $10.19
- GERN $31,918.56
- Revenue Next Year
- CMPO $6.41
- GERN $289.41
- P/E Ratio
- CMPO N/A
- GERN N/A
- Revenue Growth
- CMPO 9.13
- GERN 9199.68
- 52 Week Low
- CMPO $4.61
- GERN $1.64
- 52 Week High
- CMPO $17.71
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- CMPO 53.32
- GERN 31.98
- Support Level
- CMPO $14.34
- GERN $2.49
- Resistance Level
- CMPO $17.71
- GERN $2.84
- Average True Range (ATR)
- CMPO 0.76
- GERN 0.15
- MACD
- CMPO 0.12
- GERN -0.01
- Stochastic Oscillator
- CMPO 52.52
- GERN 13.33
About CMPO CompoSecure Inc.
CompoSecure Inc is engaged in designing and manufacturing premium financial cards. The Company's metal payment card technology and Arculus security and authentication capabilities deliver premium branded experiences which enable people to access and use their assets, and ensure trust at the point of a transaction. Its products include Metal Cards and Arculus, a digital security platform.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.